Email list hosting service & mailing list manager


Re: Clinical Trials F&A rates Paplauskas,Leonard 11 Apr 2003 18:40 EST

22.5% TDC at the UCONN Health Center, where men are men, and the women are champions!

Seriously, I did this survey about 8-10 years ago, and the national average at that time (based on an N of about 25 schools) was about 25%.  It's time to do this again, and I would be very interested in seeing the results compiled once more.

Len

Leonard P. Paplauskas
Associate Vice President for Research Administration
University of Connecticut Health Center
(Where the men ... see above)

 -----Original Message-----
 From: Joe Titone [mailto:xxxxxx@EARTHLINK.NET]
 Sent: Fri 4/11/2003 6:07 PM
 To: xxxxxx@HRINET.ORG
 Cc:
 Subject: Re: [RESADM-L] Clinical Trials F&A rates

 We don't have a separate rate for clinical trials.  You can see our rates at

 http://www.usc.edu/dept/contracts/rate.htm

 At 03:34 PM 4/11/2003 -0400, you wrote:
 >If your institution is an academic medical center involved with clinical
 >trials, could you please tell me what F&A rate your institution charges for
 >clinical trials?  The current rate at UNC is 26% but we will be reevaluating
 >that rate this year.
 >
 >Thank you,
 >
 >Tammi Jaynes RN CCRC
 >Project Manager
 >Office of Clinical Trials
 >University of North Carolina
 >919-843-2333 (office)
 >919-843-2399 (fax)
 >919-216-4385 (pager)

 ======================================================================
 Instructions on how to use the RESADM-L Mailing List, including
 subscription information and a web-searchable archive, are available
 via our web site at http://www.hrinet.org (click on "Listserv Lists")
 ======================================================================

======================================================================
 Instructions on how to use the RESADM-L Mailing List, including
 subscription information and a web-searchable archive, are available
 via our web site at http://www.hrinet.org (click on "Listserv Lists")
======================================================================